Not applicableEnded earlyNCT05061940
What this trial is testing
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Who this might be right for
Head and Neck CancerMelanomaHPV-Related Malignancy+5 more
Repertoire Immune Medicines 22